Sat, Feb 28, 2015, 10:17 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mtdsus mtdsus Oct 19, 2012 12:21 PM Flag

    NASH-Liver disease affects 2-5% of Americans -Reason for Epadel phase 2 trials.

    Vascepa some day--could be used for Liver disease--NASH-- if Epadel's Phase 2 trials are significant.
    Currently no drug has been identified if you read National Digestive Disease Information on Steato-Hepatitis.
    I do not think Amarin knows.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Mochida which sold Epadel(90% pure EPA) in Japan is trying to extend Epadel use in other big area.There are 7-20 million who suffer from this Liver disease-silently.
      It will be interesting to watch phase 2 trials for Epadel in Japan.

1.51+0.05(+3.42%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.